While the market got some intraday whipsaw action, it seemed generally good and biotechs did well- early. We had a late day sell-off with biotechs seeming to do better than.
Perhaps it is the start of the summer season but the market seems to have been quite the past couple of days or perhaps I am simply looking at the.
Outside of a not completely unexpected merger, it was a relatively quite start to the week. As has been par for the course, ASCO oncology stocks tended to be weak.
It seemed to be a quite day as I think everyone is recovering from the ASCO abstract dump. 1. I had some good discussion with people about the PGNX abstract.